This cohort study examines changes from 2010 to 2022 in use of adjuvant chemotherapy for early-stage hormone receptor–positive, ERBB2-negative breast cancer by age, genomic risk, and nodal involvement. This evidence concerns the gene ERBB2 and breast cancer.